Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug , for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic.
Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer s Disease tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
Lonza to manufacture Acumen’s monoclonal antibody, sabirnetug (ACU193), for clinical development and commercialization, if approvedSabirnetug is the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic
By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company, announced it signed an agreement with global pharmaceutical and biotech partner Lonza. The collaboration includes the manufacturing of sabirnetug (ACU193), an antibody for the treatment of Alzheimer’s disease (AD) for clinical development and commercialization, if approved. Lonza has extensive experience in antibody production, […]